Exagen Inc. to Participate in the 2022 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
February 02 2022 - 4:05PM
Exagen Inc. (Nasdaq: XGN), a leading provider of
autoimmune testing solutions, today announced its participation in
the BTIG MedTech, Digital Health, Life Science & Diagnostic
Tools Conference, which takes place February 15-17, 2022. Ron
Rocca, Exagen’s President and Chief Executive Officer, and Kamal
Adawi, Exagen’s Chief Financial Officer, will participate in a
virtual fireside chat on Wednesday, February 16 at 2:00 PM ET,
which is accessible to conference attendees. Management will also
be participating in one-on-one meetings with investors during the
event; meetings can be requested through BTIG.
About Exagen Inc.
Exagen is dedicated to transforming the care continuum for
patients suffering from debilitating and chronic autoimmune
diseases by enabling timely differential diagnosis and optimizing
therapeutic intervention. Exagen has developed and is
commercializing a portfolio of innovative testing products under
its AVISE® brand, several of which are based on our proprietary
Cell-Bound Complement Activation Products, or CB-CAPs, technology.
Exagen’s goal is to enable providers to improve care for patients
through the differential diagnosis, prognosis and monitoring of
complex autoimmune and autoimmune-related diseases, including
rheumatoid arthritis and lupus. For further information please
visit www.exagen.com.
Forward Looking Statements
Exagen cautions you that statements in this press release
regarding matters that are not historical facts are forward-looking
statements. These statements are based on Exagen's current beliefs
and expectations. The inclusion of forward-looking statements
should not be regarded as a representation by Exagen that any of
its plans will be achieved. Actual results may differ from those
set forth in this press release due to the risks and uncertainties
inherent in Exagen’s business, including, without limitation: the
COVID-19 pandemic may continue to adversely affect Exagen’s
business, financial condition and results of operations, including
as a result of shutdowns of its facilities and operations as well
as those of its suppliers and courier services, impeding patient
movement and interruptions to healthcare services causing a
decrease in test volumes, disruptions to the supply chain of
material needed for its tests, its sales and commercialization
activities and its ability to receive specimens and perform or
deliver the results from its tests, and delays in ongoing and
planned clinical trials involving its tests; Exagen’s commercial
success depends upon attaining and maintaining significant market
acceptance of its testing products and promoted therapeutics among
rheumatologists, patients, third-party payors and others in the
medical community; Exagen’s ability to successfully execute on its
business strategies; third party payors not providing coverage and
adequate reimbursement for Exagen’s testing products or promoted
therapeutics; Exagen’s ability to obtain and maintain intellectual
property protection for its testing products; regulatory
developments affecting Exagen’s business; and other risks described
in Exagen’s prior press releases and Exagen’s filings with the
Securities and Exchange Commission (SEC), including under the
heading “Risk Factors” in Exagen’s Annual Report on Form 10-K for
the year ended December 31, 2020 and any subsequent filings with
the SEC. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof,
and Exagen undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the
date hereof. All forward-looking statements are qualified in their
entirety by this cautionary statement, which is made under the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995.
Investor RelationsExagen Inc. Ryan
Douglasrdouglas@exagen.com 760.560.1525
CompanyExagen Inc.Kamal Adawi, Chief Financial
Officerkadawi@exagen.com
760.477.5514
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Jul 2023 to Jul 2024